Author:
Stratigos Alexander J.,Sekulic Aleksandar,Peris Ketty,Bechter Oliver,Prey Sorilla,Lewis Karl D.,Basset-Seguin Nicole,Chang Anne Lynn S.,Dalle Stéphane,Fernández Orland Almudena,Licitra Lisa,Robert Caroline,Ulrich Claas,Hauschild Axel,Migden Michael R.,Dummer Reinhard,Yoo Suk-Young,Okoye Emmanuel,Bassukas Ioannis,Loquai Carmen,De Giorgi Vincenzo,Eroglu Zeynep,Gutzmer Ralf,Ulrich Jens,Puig Susana,Inocencio Timothy J.,Chen Chieh-I,LaFontaine Patrick R.,Seebach Frank,Lowy Israel,Fury Matthew G.
Funder
Regeneron Pharmaceuticals Inc
Reference4 articles.
1. Management of high-risk and advanced basal cell carcinoma;Puig;Clin Transl Oncol,2015
2. Efficacy and safety of vismodegib in advanced basal-cell carcinoma;Sekulic;N Engl J Med,2012
3. Regeneron Pharmaceuticals, Inc. Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma. 2021. Accessed January 28, 2022. https://www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma-301319988.html
4. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: results from an open-label, phase 2, single-arm trial;Stratigos;Lancet Oncol,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献